Daniel Thoresen, Kenta Matsuda, Akane Urakami, Mya Myat Ngwe Tun, Takushi Nomura, Meng Ling Moi, Yuri Watanabe, Momoko Ishikawa, Trang Thi Thu Hau, Hiroyuki Yamamoto, Yuriko Suzaki, Yasushi Ami, Jonathan F Smith, Tetsuro Matano, Kouichi Morita, Wataru Akahata
Dengue virus (DENV) represents a significant global health burden, with 50% of the world's population at risk of infection, and there is an urgent need for next-generation vaccines. Virus-like particle (VLP)-based vaccines, which mimic the antigenic structure of the virus but lack the viral genome, are an attractive approach. Here, we describe a dengue VLP (DENVLP) vaccine which generates a neutralizing antibody response against all four DENV serotypes in 100% of immunized non-human primates for up to 1 year...
April 22, 2024: Journal of Virology